PMGC Holdings Inc.
ELABNasdaq
$1.07
↓ -1.8%Jul 17 close · end-of-day
Price
1Y↓ -99.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-88.1%
ROIC
—
Debt / Equity
—
Net Cash
$733,405.00
Return 1Y
-99.4%
Company profile
We are a physician-dispensed skincare company with a focus on modernizing aesthetic skincare. Elevai Labs, Inc. was incorporated in Delaware in June 2020 under the original name Reactive Medical Labs Inc. Upon completion of the stock transfer agreement, Reactive Medical Inc. became our wholly owned subsidiary. In September 2022, Reactive Medical Inc. changed its name to Elevai Research Inc. Our principal executive offices are located at 120 Newport Center Dr. #250, Newport Beach, CA 92660. As of the date of this prospectus, we are qualified to do business as a foreign corporation in the state of California. Our telephone number is 866-794-4940. Our website address is www.elevailabs.com.
- CEO
- Jordan R. Plews
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- elevailabs.com
Earnings
ELAB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$681,994.00—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $766,277.00 | $1.7M | — | $590,084.00 |
| Gross profit | $447,309.00 | $1.1M | — | $185,314.00 |
| Operating income | — | — | — | — |
| Net income | -$1.8M | -$4.3M | -$6.2M | -$7.7M |
| Diluted EPS | -$0.19 | -$0.40 | — | — |
| Operating cash flow | -$1.6M | -$4.6M | -$5.5M | -$5.9M |
| Free cash flow | — | -$4.6M | -$5.5M | -$6.4M |
| Gross margin | 58.4% | 66.2% | — | 31.4% |
| Operating margin | — | — | — | — |
| Net margin | -234.9% | -251.2% | — | -1313.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $605,529.00 | $527,478.00 | — | — | — | $285,948.00 | — | $681,994.00 |
| Gross profit | $439,254.00 | $393,901.00 | — | — | — | $78,030.00 | — | $230,474.00 |
| Operating income | -$1.4M | -$625,615.00 | — | — | — | -$2.2M | — | — |
| Net income | -$1.4M | -$1.5M | -$1.9M | -$1.6M | -$562,355.00 | -$2.6M | -$3.0M | -$5.0M |
| Diluted EPS | -$0.08 | -$0.07 | — | — | — | — | — | — |
| Operating cash flow | -$780,689.00 | -$381,678.00 | -$2.0M | -$1.3M | -$1.3M | -$1.5M | -$1.8M | -$3.0M |
| Free cash flow | -$780,689.00 | -$381,678.00 | -$2.0M | — | — | — | — | -$3.3M |
| Gross margin | 72.5% | 74.7% | — | — | — | 27.3% | — | 33.8% |
| Operating margin | -232.6% | -118.6% | — | — | — | -769.0% | — | — |
| Net margin | -233.3% | -284.6% | — | — | — | -907.3% | — | -728.3% |
Company news
Jul 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.